How MSD's Leadership Restructure can Help Facilitate Growth

MSD, known as Merck in the US and Canada, has announced a major evolution of its Human Health organisational structure, aimed at strengthening commercial execution across a broad and increasingly diverse portfolio.

The move helps to reflect the company’s commitment to sustaining leadership in key therapeutic areas while preparing for a wave of anticipated product launches.

With a robust late-stage pipeline and numerous Phase 3 trials underway, the restructuring is designed to align strategy, operations and patient access efforts more closely.

The changes underscore MSD’s focus on delivering innovative medicines and long-term value in a rapidly evolving global healthcare landscape.

MSD’s Human Health business will operate through two dedicated units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit.

This reorganisation is intended to sharpen focus in high-growth therapeutic areas while ensuring strong commercial readiness for upcoming launches.

By separating oncology from other specialty and infectious disease portfolios, the company aims to enhance agility, accountability and tailored market strategies.

Aligning business strategy goals

The restructuring comes at a pivotal time, as MSD is conducting approximately 80 Phase 3 studies. It anticipates more than 20 new growth drivers in the coming years, most with blockbuster potential.

A more specialised business unit model allows the organisation to better allocate resources. It will also streamline decision-making and optimise global launch execution across varied healthcare markets.

To lead the Oncology Business Unit, MSD has appointed Jannie Oosthuizen as Executive Vice President and President, Oncology and MSD International.

Jannie served as Senior Vice President and President of MSD Human Health US. There, he oversaw profit and loss, strategy and commercialisation efforts across the company’s domestic portfolio.

His experience in global oncology markets and track record of commercial performance position him to sustain and expand MSD’s leadership in cancer care.

New executive leadership appointments

Brian Foard will join MSD as Executive Vice President and president of the Specialty, Pharma & Infectious Diseases Business Unit, effective 2 March.

Brian served as Executive Vice President and head of the Specialty Care Business Unit at Sanofi. He managed a diverse portfolio spanning immunology, neurology, oncology and rare diseases.

Earlier in his career, he spent nearly two decades at Galderma, a Swiss pharmaceutical company specialising in dermatological treatments.

Both Jannie and Brian will report directly to Robert M. Davis, Chairman and Chief Executive Officer and serve on the company’s executive team.

“Merck is pleased to welcome Brian Foard, an experienced executive with a proven track record of strategic leadership across specialty biopharma and commercial execution,” says Robert.

“As we advance our pipeline and drive commercial success across an increasingly diversified portfolio, including a growing pipeline across Specialty, Pharma & Infectious Diseases, we are sharpening our focus on delivering innovative medicines for patients and creating long-term value for our stakeholders.”

Improving communications and access

In parallel with the business unit restructuring, MSD has appointed Chirfi Guindo as Executive Vice President, Strategic Access, Policy & Communications.

This newly integrated organisation brings together access, policy, communications and sustainability functions. This is to reinforce alignment between corporate strategy and stakeholder engagement worldwide.

By consolidating these disciplines, MSD aims to ensure consistent communication and improved access to medicines across the US and international markets.

“I am honoured to join MSD at such an important moment in its journey,” says Brian.

“MSD has a remarkable legacy of scientific leadership and a clear ambition to shape the future of medicine. Its commitment to patients, the strength of its pipeline and the caliber of its people are truly inspiring.

“I look forward to working with the teams across Specialty, Pharma & Infectious Diseases to advance innovative solutions for patients and help unlock the next phase of growth for the company.”

Chirfi, who served as senior vice president and Chief Marketing Officer, brings extensive experience across commercial strategy, global patient access and international policy.

His leadership aims to support MSD’s efforts to navigate complex regulatory environments. He will also work to expand access to innovative therapies and reinforce the company’s long-standing commitment to patients.